Suppr超能文献

开发一种放射性配体 [(3)H]LY2119620,以探测人源 M(2)和 M(4)毒蕈碱型乙酰胆碱受体变构结合位点。

Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.

机构信息

Lilly Neuroscience, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana (D.A.S., C.H.C., H.X., C.C.F.); and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia (A.C.).

Lilly Neuroscience, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana (D.A.S., C.H.C., H.X., C.C.F.); and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia (A.C.)

出版信息

Mol Pharmacol. 2014 Jul;86(1):116-23. doi: 10.1124/mol.114.091785. Epub 2014 May 7.

Abstract

In this study, we characterized a muscarinic acetylcholine receptor (mAChR) potentiator, LY2119620 (3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]thieno[2,3-b]pyridine-2-carboxamide) as a novel probe of the human M2 and M4 allosteric binding sites. Since the discovery of allosteric binding sites on G protein-coupled receptors, compounds targeting these novel sites have been starting to emerge. For example, LY2033298 (3-amino-5-chloro-6-methoxy-4-methyl-thieno(2,3-b)pyridine-2-carboxylic acid cyclopropylamid) and a derivative of this chemical scaffold, VU152100 (3-amino-N-(4-methoxybenzyl)-4,6-dim​ethylthieno[2,3-b]pyridine carboxamide), bind to the human M4 mAChR allosteric pocket. In the current study, we characterized LY2119620, a compound similar in structure to LY2033298 and binds to the same allosteric site on the human M4 mAChRs. However, LY2119620 also binds to an allosteric site on the human M2 subtype. [(3)H]NMS ([(3)H]N-methylscopolamine) binding experiments confirm that LY2119620 does not compete for the orthosteric binding pocket at any of the five muscarinic receptor subtypes. Dissociation kinetic studies using [(3)H]NMS further support that LY2119620 binds allosterically to the M2 and M4 mAChRs and was positively cooperative with muscarinic orthosteric agonists. To probe directly the allosteric sites on M2 and M4, we radiolabeled LY2119620. Cooperativity binding of [(3)H]LY2119620 with mAChR orthosteric agonists detects significant changes in Bmax values with little change in Kd, suggesting a G protein-dependent process. Furthermore, [(3)H]LY2119620 was displaced by compounds of similar chemical structure but not by previously described mAChR allosteric compounds such as gallamine or WIN 62,577 (17-β-hydroxy-17-α-ethynyl-δ-4-androstano[3,2-b]pyrimido[1,2-a]benzimidazole). Our results therefore demonstrate the development of a radioligand, [(3)H]LY2119620 to probe specifically the human M2 and M4 muscarinic receptor allosteric binding sites.

摘要

在这项研究中,我们描述了一种毒蕈碱乙酰胆碱受体 (mAChR) 增效剂 LY2119620(3-氨基-5-氯-N-环丙基-4-甲基-6-[2-(4-甲基哌嗪-1-基)-2-氧代乙氧基]噻吩[2,3-b]吡啶-2-甲酰胺),作为人类 M2 和 M4 变构结合位点的新型探针。自从在 G 蛋白偶联受体上发现变构结合位点以来,靶向这些新型位点的化合物开始出现。例如,LY2033298(3-氨基-5-氯-6-甲氧基-4-甲基噻吩[2,3-b]吡啶-2-羧酸环丙基酰胺)和这种化学结构的衍生物 VU152100(3-氨基-N-(4-甲氧基苄基)-4,6-二甲基噻吩[2,3-b]吡啶甲酰胺)与人类 M4 mAChR 的变构口袋结合。在目前的研究中,我们描述了 LY2119620,一种与 LY2033298 结构相似的化合物,与人类 M4 mAChRs 的相同变构位点结合。然而,LY2119620 也与人类 M2 亚型的变构位点结合。[(3)H]NMS([(3)H]N-甲基东莨菪碱)结合实验证实,LY2119620 不会与五种毒蕈碱受体亚型的任何一个变构结合口袋竞争。使用 [(3)H]NMS 的离解动力学研究进一步支持 LY2119620 与 M2 和 M4 mAChR 变构结合,并且与毒蕈碱原激动剂呈正协同作用。为了直接探测 M2 和 M4 上的变构位点,我们对 LY2119620 进行了放射性标记。[(3)H]LY2119620 与 mAChR 原激动剂的协同结合检测到 Bmax 值的显著变化,而 Kd 值变化很小,这表明这是一个 G 蛋白依赖性的过程。此外,[(3)H]LY2119620 被具有相似化学结构的化合物置换,但不能被先前描述的 mAChR 变构化合物如 gallamine 或 WIN 62,577(17-β-羟基-17-α-乙炔基-δ-4-雄烷[3,2-b]嘧啶并[1,2-a]苯并咪唑)置换。因此,我们的结果证明了一种放射性配体 [(3)H]LY2119620 的开发,该配体可特异性探测人类 M2 和 M4 毒蕈碱受体变构结合位点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验